Overall, the data published in the study is not sufficient to establish a causal association between GLP-1 receptor agonist use and NAION, the Danish drugmaker said, adding that the condition is not an adverse drug reaction for the marketed formulations of semaglutide. SEE ALSO NAION more often affects older individuals
When someone needs to stay on a psychiatric medication thats working for their mental health but is causing problematic weight gain, adding a low-dose GLP-1 might allow them to maintain their psychiatric stability while addressing the metabolic consequences
Eli Lilly) and others race to expand their cardiometabolic portfolios, innovative approaches that promise more effective weight loss or fewer side effects could set new therapies apart
In reality, no, Ipamorelin does not typically make you hungry
We believe that the mechanistic pathways uncovered here have potential for impact in the clinical context of IRI, for which no approved therapies currently exist